Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib∗

Bibliographic Details
Main Authors:	Andrew J. Piper-Vallillo, MD, Lecia V. Sequist, MD, MPH
Format:	Article
Language:	English
Published:	Elsevier 2019-12-01
Series:	JACC. CardioOncology
Subjects:	cardiotoxicity EGFR NSCLC osimertinib
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666087319300973

id	doaj-7f63c1f86ebe442887ff64173609f9c3
record_format	Article
spelling	doaj-7f63c1f86ebe442887ff64173609f9c32020-11-25T03:38:21ZengElsevierJACC. CardioOncology2666-08732019-12-0112179181Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib∗Andrew J. Piper-Vallillo, MD0Lecia V. Sequist, MD, MPH1Beth Israel Deaconess Medical Center, Boston, Massachusetts; Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, MassachusettsMassachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts; Address for correspondence: Dr. Lecia V. Sequist, Massachusetts General Hospital, 55 Fruit Street, BHX-1.125, Boston, Massachusetts 02114.http://www.sciencedirect.com/science/article/pii/S2666087319300973cardiotoxicityEGFRNSCLCosimertinib
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Andrew J. Piper-Vallillo, MD Lecia V. Sequist, MD, MPH
spellingShingle	Andrew J. Piper-Vallillo, MD Lecia V. Sequist, MD, MPH Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib∗ JACC. CardioOncology cardiotoxicity EGFR NSCLC osimertinib
author_facet	Andrew J. Piper-Vallillo, MD Lecia V. Sequist, MD, MPH
author_sort	Andrew J. Piper-Vallillo, MD
title	Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib∗
title_short	Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib∗
title_full	Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib∗
title_fullStr	Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib∗
title_full_unstemmed	Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib∗
title_sort	cardiac risk-informed treatment of egfr-mutant lung cancer with osimertinib∗
publisher	Elsevier
series	JACC. CardioOncology
issn	2666-0873
publishDate	2019-12-01
topic	cardiotoxicity EGFR NSCLC osimertinib
url	http://www.sciencedirect.com/science/article/pii/S2666087319300973
work_keys_str_mv	AT andrewjpipervallillomd cardiacriskinformedtreatmentofegfrmutantlungcancerwithosimertinib AT leciavsequistmdmph cardiacriskinformedtreatmentofegfrmutantlungcancerwithosimertinib
_version_	1724542647671980032

Cardiac Risk-Informed Treatment of EGFR-Mutant Lung Cancer With Osimertinib∗

Similar Items